Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

Benutzer: Gast

Titel:: Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
Dokumenttyp:: Zeitschriftenaufsatz
Autor(en):: Ortiz, Stephan ; Pittock, Sean J. ; Berthele, Achim ; Levy, Michael ; Nakashima, Ichiro ; Oreja-Guevara, Celia ; Allen, Kerstin ; Mashhoon, Yasmin ; Parks, Becky ; Kim, Ho Jin
Stichworte:: Neurology ; autoimmune ; complement ; exposure-response analysis ; neuromyelitis optica spectrum disorder ; pharmacokinetics ; pharmacodynamics ; ravulizumab
Zeitschriftentitel:: Frontiers in Neurology
Jahr:: 2024
Band / Volume:: 15
Volltext / DOI:: doi:10.3389/fneur.2024.1332890
Verlag / Institution:: Frontiers Media S.A.
E-ISSN:: 1664-2295
Publikationsdatum:: 31.01.2024
CC-Lizenz:: by, https://creativecommons.org/licenses/by/4.0

BibTeX

Vorkommen: